#China #Suzhou #MASH #Ribo Life Science #Madrigal Pharmaceuticals

Ribo and Madrigal's Collaborative Breakthrough in siRNA Therapies for MASH

In a significant advancement in the fight against metabolic dysfunction-associated steatohepatitis (MASH), Suzhou Ribo Life Science Co., Ltd. and its subsidiary, Ribocure Pharmaceuticals AB, have partnered with Madrigal Pharmaceuticals to make notable strides in developing novel small interfering RNA (siRNA) therapies. This collaboration marks a vital first milestone, indicating rapid progress within a few months of their partnership.

MASH is a concerning medical condition characterized by fat accumulation in the liver, often linked to metabolic syndrome, which can lead to serious health issues, including liver cirrhosis and liver cancer. The recent accomplishment from Ribo and Madrigal highlights a shared commitment to addressing the pressing need for innovative treatments in the field of liver disease. Both companies are joining forces to explore several preclinical projects that aim to broaden the therapeutic possibilities targeting liver health, specifically within MASH treatment.

Li-Ming Gan, co-CEO and global president of research and development at Ribo, expressed enthusiasm about progressing towards this key milestone. He said, “We are thrilled to have achieved this major milestone in our MASH program in collaboration with Madrigal within just a few months. Madrigal has established itself as a prominent player in the market, possessing deep clinical expertise in MASH, while Ribo brings world-class capabilities in siRNA drug discovery and delivery technologies. Our complementary strengths have expedited the advancement of this project.” The partnership represents a fusion of Ribo’s cutting-edge siRNA technology with Madrigal's extensive clinical insights, solidifying their ability to develop effective solutions for MASH.

Furthermore, the immediate next steps involve launching new drug studies aimed at supporting upcoming clinical trials. The focus will primarily be on refining the prospective candidates and ensuring they align with the particular medical needs of patients suffering from this challenging condition.

Suzhou Ribo Life Science, listed under (06938.HK), is an innovative clinical-stage biotech company dedicated to the product development of nucleic acid-based therapeutics. With an integrated vertical technology platform, Ribo has cultivated a robust product portfolio that addresses serious medical conditions where unmet medical needs are prevalent. The subsidiary Ribocure Pharmaceuticals is focused on developing life-saving oligonucleotide therapies, with efforts directed towards pipeline advancement and the exploration of new therapeutic targets.

Through cutting-edge research and development, the collaboration anticipates not only advancing the field of siRNA-based treatments but also improving patient outcomes for those affected by persistent liver diseases such as MASH. The companies stress the urgency and importance of their work, as the demand for effective treatments continues to escalate in global healthcare.

In conclusion, the partnership between Ribo and Madrigal showcases a significant step forward in the biotechnology arena, specifically for liver-related treatments. As clinical trials approach, both organizations remain dedicated to innovating solutions and ultimately transforming the treatment landscape for patients battling metabolic dysfunction-associated complications.